Key Capital announced positive results for its liver cancer immunotherapy product hepcortespenlisimut-L.
Here's what you should know.
1. Hepcortespenlisimut-L is a once daily tablet of an oral immunotherapeutic vaccine.
2. Key Capital proved it was safe and highly effective in treating 75 advanced liver cancer patients through a phase II study.
3. More than 90 percent of patients were alive after a 12 month follow-up. A competitor product touts a 10 percent survival rate.
4. After two months, 50 of the 75 patients had their hepatic tumor marker decline, indicating a 66.7 percent response rate.
5. Twelve patients had normal alpha-fetoprotein levels experienced tumor clearance.
6. Researchers observed no adverse events at the time.
7. Key Capital is in the midst of a phase III study at Mongolian National Cancer Center in China.